Results 141 to 150 of about 109,968 (264)

Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy. [PDF]

Kidney Med
Shivaraj K, Mamlouk O, Tchakarov A, Patel K, Abudayyeh A.   +4 more
europepmc   +1 more source

Immunoinformatics‐Based Design of a Multi‐Epitope Vaccine Targeting a Conserved Copper–Associated Protein in Neisseria gonorrhoeae

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Neisseria gonorrhoeae poses an urgent public health challenge due to rapidly increasing antimicrobial resistance and the absence of an effective vaccine. Targeting conserved bacterial pathways involved in essential physiological processes may provide new opportunities for vaccine antigen discovery.
Sinethemba H. Yakobi, Uchechukwu U. Nwodo   +1 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy. [PDF]

Int J Mol Sci
Cohen I, Lebel E, Grisariu S, Avni B, Kfir-Erenfeld S, Asherie N, Zimran E, Vainstein V, Assayag M, Sharon TD, Alexander-Shani R, Bessig N, Shehadeh A, Ishtay A, Schlossberg M, Pick M, Gatt ME, Bdolah-Abram T, Stepensky P, Elias S.   +19 more
europepmc   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source

Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System. [PDF]

Immun Inflamm Dis
Yao SY, Du MQ, Yang H, Zeng QM, Zhou H, Zhang X, Kazuo S, Liu J, Lin LX, Kang XH, Jiang DY, Peng Y.   +11 more
europepmc   +1 more source

Reply to “Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence”

Annals of Neurology, EarlyView.
Gabriel Cerono, Bruce A. C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. [PDF]

World J Clin Oncol
Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F.   +4 more
europepmc   +1 more source

Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update

British Journal of Clinical Pharmacology, EarlyView.
Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel, Adeline Benis, Philippe Bonniaud, Jean‐Luc Faillie, Aurélie Grandvuillemin   +4 more
wiley   +1 more source